HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulation/Legislation (Wellness)

Set Alert for Regulation {Wellness}


Set Alert for Regulation {Wellness}

Latest From Wellness & Regulation

Califf Clears First Senate Hurdle, But FDA Decision On Abortion Pill May Complicate Final Confirmation

Republican opposition to Califf over agency’s recent move to relax its Mifeprex restrictions is ominous since, in order be confirmed as commissioner, he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to pharma industry.

FDA Leadership

Magnesium Qualified Health Claims For Reducing Risk Of Hypertension Authorized In US

CFSAN decides on Center for Magnesium Education and Research LLC's 2016 petition requesting FDA authorize a qualified health claim about relationship between magnesium and reduced risk of high blood pressure, or hypertension.

Dietary Supplements FDA

Omicron Forces US FDA To Again Pause ‘Certain Inspectional Activities’

COVID-19 pandemic’s latest variant has pushed FDA to pump brakes again on performing on-site surveillance inspections through at least 19 January. Meanwhile, associate commissioner says Remote Regulatory Assessments “are here to stay.”

Coronavirus COVID-19 FDA
See All

Latest From Wellness & Legislation

Manchin’s Build Back Better Battle Could Sink Restoring FTC Monetary Relief Authority

Members of Congress in favor of giving FTC authority to impose monetary relief orders against firms linked to false advertising likely were caught off guard when West Virginia Democrat said he wouldn’t vote for legislation with $2.2 trillion for climate change, tax and social programs that President Biden made a primary plank of his Capitol Hill strategy and that the House passed in November.

Ad Complaints Consumer

Oregon’s Proposed Limits On Cannabinoid Sales Hit Hemp Trade Group As 'Dangerous Precedent'

US Hemp Roundtable submits comments on proposed rule as well as surveys hemp and cannabinoid product market stakeholders “to demonstrate the devastating impact the new rules would have on farmers, retailers and consumers.”

Cannabidiol CBD Dietary Supplements

With Data Coming Slowly On Cannabis, Hemp Ingredients, FDA Launches ‘Acceleration Plan’

Cannabis-Derived Products Data Acceleration Plan aims to avoid same conclusion already found in FDA's more-than two-year search for information on using cannabis ingredients in supplements, food and beverages and personal care topicals: too little is available to determine safety.

Dietary Supplements FDA
See All